PTGX Protagonist Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PTGX

Price (delayed)

$17.69

Market cap

$1.02B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.63

Enterprise value

$791.6M

Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. Rusfertide (PTG-300) is an injectable hepcidin mimetic in a Phase 2 ...

Highlights
The debt has dropped by 57% year-on-year and by 26% since the previous quarter
The equity has grown by 24% YoY and by 2.7% from the previous quarter
The quick ratio has soared by 58% YoY but it has contracted by 3% from the previous quarter
Protagonist Therapeutics's revenue has shrunk by 100% YoY
PTGX's gross profit has plunged by 100% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.protagonist-inc.com
Peers: OMGA

Key stats

What are the main financial stats of PTGX
Market
Shares outstanding
57.68M
Market cap
$1.02B
Enterprise value
$791.6M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.37
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$140.48M
EBITDA
-$137.16M
Free cash flow
-$119.49M
Per share
EPS
-$2.63
Free cash flow per share
-$2.02
Book value per share
$5.25
Revenue per share
$0
TBVPS
$5.58
Balance sheet
Total assets
$330.02M
Total liabilities
$27.87M
Debt
$1.8M
Equity
$302.15M
Working capital
$297.01M
Liquidity
Debt to equity
0.01
Current ratio
11.66
Quick ratio
11.51
Net debt/EBITDA
1.67
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-49.4%
Return on equity
-54.7%
Return on invested capital
-174.9%
Return on capital employed
-46.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PTGX stock price

How has the Protagonist Therapeutics stock price performed over time
Intraday
0.97%
1 week
5.11%
1 month
25.64%
1 year
135.55%
YTD
62.14%
QTD
6.06%

Financial performance

How have Protagonist Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$153.22M
Net income
-$140.48M
Gross margin
N/A
Net margin
N/A
Protagonist Therapeutics's revenue has shrunk by 100% YoY
PTGX's gross profit has plunged by 100% YoY
PTGX's operating income is down by 16% year-on-year and by 4.1% since the previous quarter
The net income has declined by 8% year-on-year and by 2.1% since the previous quarter

Growth

What is Protagonist Therapeutics's growth rate over time

Valuation

What is Protagonist Therapeutics stock price valuation
P/E
N/A
P/B
3.37
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Protagonist Therapeutics's EPS has increased by 2.2% QoQ
The equity has grown by 24% YoY and by 2.7% from the previous quarter
The P/B is 19% less than the last 4 quarters average of 4.1
Protagonist Therapeutics's revenue has shrunk by 100% YoY

Efficiency

How efficient is Protagonist Therapeutics business performance
The ROIC has plunged by 118% YoY and by 10% from the previous quarter
PTGX's ROA is down by 22% year-on-year but it is up by 2.2% since the previous quarter
The company's return on equity fell by 17% YoY but it rose by 3.7% QoQ

Dividends

What is PTGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PTGX.

Financial health

How did Protagonist Therapeutics financials performed over time
The quick ratio has soared by 58% YoY but it has contracted by 3% from the previous quarter
The current ratio has surged by 55% year-on-year but it has declined by 2.9% since the previous quarter
The debt is 99% smaller than the equity
The debt has dropped by 57% year-on-year and by 26% since the previous quarter
The debt to equity has plunged by 50% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.